News

Multipronged approach to overcome the challenge of anti-drug antibodies to serve as the foundation of new subsidiary, AdaMunix ROCKVILLE, Maryland, […]

Full report from UroToday: https://www.urotoday.com/conference-highlights/asco-2025/asco-2025-prostate-cancer/160813-asco-2025-preserve-006-phase-1-study-of-gotistobart-bnt316-onc-392-in-combination-with-lutetium-lu-177-vipivotide-tetraxetan-in-patients-with-mcrpc.html

Oral presentation will feature AI-081, a potentially best-in-class PD-1/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 antibody Initial Phase 1 […]

ROCKVILLE, Maryland, December 2, 2024 (GLOBE NEWSWIRE) –– OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer and neurological […]

Our merger announcement of OncoC4 with AcroImmune has generated great excitement from multiple major news outlets, and here are some […]